Difference between revisions of "Vascular sarcoma"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "==[https://www.nccn.org/ NCCN]==" to "==NCCN==") |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 3: | Line 3: | ||
[[#top|Back to Top]] | [[#top|Back to Top]] | ||
</div> | </div> | ||
| − | {{#lst: | + | {{#lst:Editorial board transclusions|sarcoma}} |
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
| Line 14: | Line 14: | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
=Guidelines= | =Guidelines= | ||
| + | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' | ||
==[http://www.esmo.org/ ESMO]== | ==[http://www.esmo.org/ ESMO]== | ||
| − | *[ | + | *[https://www.sciencedirect.com/science/article/pii/S0923753419340876?via%3Dihub Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014)] [https://pubmed.ncbi.nlm.nih.gov/25210080/ PubMed] |
| − | == | + | |
| − | *[https://www.nccn.org/ | + | ==NCCN== |
| + | *[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1464 NCCN Guidelines - Soft Tissue Sarcoma] | ||
=Hemangioendothelioma, all lines of therapy= | =Hemangioendothelioma, all lines of therapy= | ||
=Hemangiopericytoma (solitary fibrous tumor), all lines of therapy= | =Hemangiopericytoma (solitary fibrous tumor), all lines of therapy= | ||
Revision as of 11:30, 13 May 2024
| Section editor | |
|---|---|
 |
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN, USA |
0 regimens on this page
0 variants on this page
|
Note: this page does not contain any regimens. The following links will take you to disease-specific pages with regimens:
- Regimens for Angiosarcoma are here.
- Regimens for Kaposi sarcoma are here.
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
ESMO
- Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014) PubMed